Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may often only indicate exposure to the virus, not protections against reinfection.
- Football-loving states slow to enact youth concussion laws
- Lab results don’t explain ‘obesity paradox,’ but bias may
- New device offers faster way to detect antibiotic-resistant bacteria
- Flashy lizards are more attractive to mates and to predators
- Octapharma USA presents bleeding disorders research at virtual ASH annual meeting